297 related articles for article (PubMed ID: 29098396)
21. Poor prognosis of male triple-positive breast Cancer patients: a propensity score matched SEER analysis and molecular portraits.
Wang B; Wang H; Zhao A; Zhang M; Yang J
BMC Cancer; 2021 May; 21(1):523. PubMed ID: 33964913
[TBL] [Abstract][Full Text] [Related]
22. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer.
Xu S; Yang Y; Tao W; Song Y; Chen Y; Ren Y; Liu J; Pang D
Breast Cancer Res Treat; 2012 Nov; 136(2):495-502. PubMed ID: 23065002
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Korean Male Breast Cancer Using an Online Nationwide Breast-Cancer Database: Matched-Pair Analysis of Patients With Female Breast Cancer.
Choi MY; Lee SK; Lee JE; Park HS; Lim ST; Jung Y; Ko BK; Nam SJ;
Medicine (Baltimore); 2016 Apr; 95(16):e3299. PubMed ID: 27100414
[TBL] [Abstract][Full Text] [Related]
24. The relative benefits of tamoxifen in older women with T1 early-stage breast cancer treated with breast-conserving surgery and radiation therapy.
Khan AJ; Parikh RR; Neboori HJ; Goyal S; Haffty BG; Moran MS
Breast J; 2013; 19(5):490-5. PubMed ID: 23800027
[TBL] [Abstract][Full Text] [Related]
25. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM
Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889
[TBL] [Abstract][Full Text] [Related]
26. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
Erman A; Nugent A; Amir E; Coyte PC
Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for male breast cancer: similarity to female counterparts.
Yu E; Stitt L; Vujovic O; Joseph K; Assouline A; Au J; Younus J; Perera F; Tai P
Anticancer Res; 2013 May; 33(5):2227-31. PubMed ID: 23645780
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis.
Jiang M; Chen W; Hu Y; Chen C; Li H
Medicine (Baltimore); 2021 Aug; 100(33):e26949. PubMed ID: 34414958
[TBL] [Abstract][Full Text] [Related]
30. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis.
Hadji P; Ziller V; Kyvernitakis J; Bauer M; Haas G; Schmidt N; Kostev K
Breast Cancer Res Treat; 2013 Feb; 138(1):185-91. PubMed ID: 23334803
[TBL] [Abstract][Full Text] [Related]
31. Similarities and differences in the characteristics and primary treatment of breast cancer in men and women - a population based study (Sweden).
Nilsson C; Holmqvist M; Bergkvist L; Hedenfalk I; Lambe M; Fjällskog ML
Acta Oncol; 2011 Oct; 50(7):1083-8. PubMed ID: 21830994
[TBL] [Abstract][Full Text] [Related]
32. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
[TBL] [Abstract][Full Text] [Related]
33. Comparison between male and female breast cancer survival using propensity score matching analysis.
Scomersi S; Giudici F; Cacciatore G; Losurdo P; Fracon S; Cortinovis S; Ceccherini R; Zanconati F; Tonutti M; Bortul M
Sci Rep; 2021 Jun; 11(1):11639. PubMed ID: 34079019
[TBL] [Abstract][Full Text] [Related]
34. Management of male breast cancer in the United States: a surveillance, epidemiology and end results analysis.
Fields EC; DeWitt P; Fisher CM; Rabinovitch R
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):747-52. PubMed ID: 24138917
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.
Ishizuna K; Ninomiya J; Ogawa T; Tsuji E; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y; Oya M
Gan To Kagaku Ryoho; 2014 Aug; 41(8):965-70. PubMed ID: 25132027
[TBL] [Abstract][Full Text] [Related]
36. Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.
Wu Q; Li J; Zhu S; Wu J; Li X; Liu Q; Wei W; Sun S
Oncotarget; 2016 Dec; 7(52):87532-87542. PubMed ID: 27655704
[TBL] [Abstract][Full Text] [Related]
37. Male breast cancer: Outcome with adjuvant treatment.
Yadav BS; Sharma SC; Singh R; Dahiya D; Ghoshal S
J Cancer Res Ther; 2020; 16(6):1287-1293. PubMed ID: 33342786
[TBL] [Abstract][Full Text] [Related]
38. Male breast cancer: A closer look at patient and tumor characteristics and factors associated with survival.
Zhao J; Wang B; Zhao J; Mao Y; Liu J; Yang Y
Thorac Cancer; 2020 Nov; 11(11):3107-3116. PubMed ID: 32930510
[TBL] [Abstract][Full Text] [Related]
39. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
40. Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study.
Schrading S; Schild H; Kühr M; Kuhl C
Radiology; 2014 Apr; 271(1):45-55. PubMed ID: 24475835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
